« Return to News | Drug Sponsors

Astellas exercises buy-out option for Perseid

Friday, March 18, 2011 01:35 PM

Astellas Pharma has exercised a buy-out option to acquire all of Maxygen’s ownership interest in Perseid Therapeutics, the joint venture between Maxygen and Astellas, according to Fierce Biotech.  Maxygen and Perseid are based in Redwood City, Calif.

They formed the collaboration in 2009 to focus on the discovery and R&D of multiple protein pharmaceutical programs, including Maxygen's MAXY-4 program. The transaction is expected to close within three months.  

Astellas will pay Maxygen $76 million, and Perseid will become its wholly-owned subsidiary. In addition, Astellas will become sole owner of the MAXY-4 program. The MAXY-4 proteins are intended to reduce T-cell activation and lessen the immune response in rheumatoid arthritis and transplant rejection.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.